MX2021001264A - Métodos para tratar la vejiga hiperactiva con el uso de trospio. - Google Patents

Métodos para tratar la vejiga hiperactiva con el uso de trospio.

Info

Publication number
MX2021001264A
MX2021001264A MX2021001264A MX2021001264A MX2021001264A MX 2021001264 A MX2021001264 A MX 2021001264A MX 2021001264 A MX2021001264 A MX 2021001264A MX 2021001264 A MX2021001264 A MX 2021001264A MX 2021001264 A MX2021001264 A MX 2021001264A
Authority
MX
Mexico
Prior art keywords
methods
trospium
overactive bladder
bladder
treating overactive
Prior art date
Application number
MX2021001264A
Other languages
English (en)
Spanish (es)
Inventor
Dennis Giesing
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2021001264A publication Critical patent/MX2021001264A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0266—Shape memory materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1085—Bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
MX2021001264A 2018-08-01 2019-07-31 Métodos para tratar la vejiga hiperactiva con el uso de trospio. MX2021001264A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862713414P 2018-08-01 2018-08-01
US201962850481P 2019-05-20 2019-05-20
PCT/US2019/044478 WO2020028554A1 (en) 2018-08-01 2019-07-31 Methods of treating overactive bladder using trospium

Publications (1)

Publication Number Publication Date
MX2021001264A true MX2021001264A (es) 2021-07-02

Family

ID=69232612

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001264A MX2021001264A (es) 2018-08-01 2019-07-31 Métodos para tratar la vejiga hiperactiva con el uso de trospio.

Country Status (10)

Country Link
US (2) US11464734B2 (enExample)
EP (1) EP3829582A4 (enExample)
JP (2) JP2021532155A (enExample)
KR (1) KR20210039403A (enExample)
CN (1) CN112839653A (enExample)
AU (1) AU2019315957A1 (enExample)
BR (1) BR112021001337A2 (enExample)
CA (1) CA3107461A1 (enExample)
MX (1) MX2021001264A (enExample)
WO (1) WO2020028554A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150250717A1 (en) 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
JOP20200124A1 (ar) 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
KR20210039403A (ko) 2018-08-01 2021-04-09 타리스 바이오메디컬 엘엘씨 트로스피움을 사용한 과민성 방광의 치료 방법

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2125696T3 (es) * 1996-11-27 1999-03-01 Pfleger R Chem Fab Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
MX2013000002A (es) * 2001-07-27 2013-04-29 Teva Womens Health Inc Metodos de tratamiento de condiciones patologicas asociadas con vejiga hiperactiva.
US20060058777A1 (en) 2002-12-11 2006-03-16 Pia Norup Nielsen Urinary catheter device with a pharmaceutically active composition
CA2513188A1 (en) 2003-01-16 2004-08-05 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
CA2552677A1 (en) * 2004-01-13 2005-07-28 Vasogenix Pharmaceuticals, Inc. Controlled release cgrp delivery composition for cardiovascular and renal indications
ES2322148T3 (es) 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
US20060128808A1 (en) * 2004-10-20 2006-06-15 Galderma Research & Development, S.N.C. Method of using adapalene in acne maintenance therapy
US20060217405A1 (en) 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US7390816B2 (en) * 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
JP5265359B2 (ja) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー 膀胱内薬物送達デバイスおよび方法
RU2435610C2 (ru) 2005-09-02 2011-12-10 Теравида, Инк. Терапия для лечения заболевания
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
US9586035B2 (en) 2007-12-11 2017-03-07 Massachusetts Institute Of Technology Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
AU2010265863C1 (en) 2009-06-26 2012-11-01 Taris Biomedical Llc Implantable drug delivery devices and methods of making the same
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
AU2010339821B2 (en) 2009-12-17 2015-02-19 Taris Biomedical Llc Implantable device with intravesical tolerability and methods of treatment
SMT202000670T1 (it) 2010-08-05 2021-01-05 Taris Biomedical Llc Dispositivo e kit di somministrazione di farmaci per stent ureterale
JP5945544B2 (ja) 2010-10-06 2016-07-05 タリス バイオメディカル エルエルシー 時間選択的に生体吸収可能または崩壊可能な薬剤送達システムおよび方法
CA2823783C (en) 2011-01-10 2023-03-21 Taris Biomedical, Inc. Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
RU2598057C2 (ru) 2011-02-04 2016-09-20 ТАРИС Биомедикал ЛЛК Имплантируемое устройство для контролируемого высвобождения лекарственного средства с низкой растворимостью
SI2890384T1 (sl) * 2012-08-31 2022-02-28 Taris Biomedical Llc Sistemi za dostavo zdravila in postopki za zdravljenje raka sečnega mehurja, ki obsegajo oksaliplatin
BR112015004110A2 (pt) 2012-08-31 2017-07-04 Taris Biomedical Llc sistemas e métodos de distribuição de drogas para tratamento de próstata
SG11201502104YA (en) * 2012-09-18 2015-05-28 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium
EP2719374A1 (en) 2012-10-12 2014-04-16 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Drug delivery device
EP2964310A1 (en) 2013-03-05 2016-01-13 TARIS Biomedical LLC Drug delivery devices and methods for controlled drug release through device orifice
HUE072250T2 (hu) 2013-03-15 2025-11-28 Taris Biomedical Llc Gyógyszeradagoló eszközök gyógyszeráteresztõ résszel
US9814671B2 (en) 2013-03-15 2017-11-14 Taris Biomedical Llc Drug delivery devices and methods for drug delivery
ES2956840T3 (es) 2013-08-19 2023-12-29 Taris Biomedical Llc Dispositivos de administración de fármacos de múltiples unidades
CA2929554A1 (en) 2013-11-05 2015-05-14 Taris Biomedical Llc Osmotic drug delivery devices, kits, and methods
US20150250717A1 (en) 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
US10737078B2 (en) 2014-06-26 2020-08-11 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
KR102658706B1 (ko) 2015-04-23 2024-04-17 타리스 바이오메디컬 엘엘씨 약물-투과성 성분을 구비한 약물 전달 장치 및 방법
EP3347036A1 (en) * 2015-09-10 2018-07-18 Assistance Publique - Hôpitaux de Paris Use of interleukin 2 for treating spondyloarthritis
JP6283440B1 (ja) * 2016-10-27 2018-02-21 Ｅａファーマ株式会社 逆流性食道炎の再発抑制剤
SMT202100310T1 (it) 2017-02-01 2021-07-12 Taris Biomedical Llc Dispositivi per la deposizione di farmaci in vivo
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
KR20210039403A (ko) 2018-08-01 2021-04-09 타리스 바이오메디컬 엘엘씨 트로스피움을 사용한 과민성 방광의 치료 방법

Also Published As

Publication number Publication date
AU2019315957A1 (en) 2021-02-18
EP3829582A4 (en) 2022-04-27
CN112839653A (zh) 2021-05-25
BR112021001337A2 (pt) 2021-04-20
US20230075003A1 (en) 2023-03-09
CA3107461A1 (en) 2020-02-06
US12133913B2 (en) 2024-11-05
JP2024164020A (ja) 2024-11-26
WO2020028554A1 (en) 2020-02-06
KR20210039403A (ko) 2021-04-09
JP2021532155A (ja) 2021-11-25
US11464734B2 (en) 2022-10-11
EP3829582A1 (en) 2021-06-09
US20200060966A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
WO2019246262A3 (en) Methods of treating or inhibiting onset of huntington's disease
EP4218804A3 (en) Use of myostatin inhibitors and combination therapies
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
PH12021552024A1 (en) Treatment of kidney injury
EP4371554A3 (en) Use of sublingual dexmedetomidine for the treatment of agitation
JOP20200035A1 (ar) تركيبات حمض أميني لعلاج الإصابات العصبية
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2020005547A (es) Moduladores de la actividad del complemento.
MY194227A (en) Modulators of pcsk9 expression
JOP20200298A1 (ar) مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها
MY200352A (en) Modulators of apol1 expression
SG11201903725UA (en) Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
EP4324454A3 (en) Cross-linking agents and associated methods
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2022012366A (es) Metodos para generar neuronas de dopamina del mesencefalo, neuronas del mesencefalo, y usos de las mismas.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
MX2022004524A (es) Tratamiento génico para la enfermedad de alzheimer.
MX2021005758A (es) Moduladores de la expresión de irf5.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2022010456A (es) Compuestos heterocíclicos para modular la subfamilia de receptores nucleares 2, grupo f, miembro 6.
IL308628A (en) Methods for treating type 1 diabetes
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
PH12021551975A1 (en) Use of vibegron to treat overactive bladder